Johnson & Johnson raises guidance and declares USD 1.34 dividend per Johnson & Johnson stock

Published on 10/14/2026 at 12:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter sales reached USD 25.4 billion on October 13, 2026. Johnson & Johnson stock trades at EUR 223.58, 0.64 percent above its Xetra close.

Guidance and dividend update

Third-quarter sales reached USD 25.4 billion on October 13, 2026.
Johnson & Johnson declared a USD 1.34 dividend with a November 24, 2026 ex-date.
Johnson & Johnson stock trades at EUR 223.58 at 12:13 p.m. CEST at Lang & Schwarz on October 14, 2026, 0.64 percent above the Xetra close of October 13, 2026.
MedTech operational sales grew 2.5 percent, compared with 7.9 percent for Innovative Medicine.

Wissenschaftler in Pharma-Labor mit Impfstoffampullen und Laborgeräten — Fotorealistisches Pharma-Labor zeigt Forschung von Johnson & Johnson, ISIN US4781601046, mit Wissenschaftlern und Impfstoffen, Illustration mit AI erstellt.

Johnson & Johnson (ISIN US4781601046) raised its 2026 outlook and declared a USD 1.34 dividend per share on October 13, 2026. The company reported third-quarter sales of USD 25.399 billion, while Johnson & Johnson stock was trading at EUR 223.58 at Lang & Schwarz on October 14, 2026.

Three dated corporate events

On July 29, 2026, Johnson & Johnson's earlier outlook set the reported sales midpoint at USD 101.1 billion, according to Johnson & Johnson. On October 13, 2026, the company reported third-quarter sales of USD 25.399 billion, up from USD 23.993 billion in the third quarter of 2025, and adjusted earnings per share of USD 2.59 versus USD 2.80 a year earlier.

Also on October 13, 2026, Johnson & Johnson lifted its reported sales midpoint to USD 101.2 billion and its adjusted earnings-per-share midpoint to USD 11.10 for fiscal 2026. The guidance change gives the results a clear forward-looking dimension, although the reported third-quarter net earnings figure was USD 210 million after special items.

What does the mix mean for margins?

The operating split explains why the higher outlook does not remove execution concerns. Innovative Medicine operational sales grew 7.9 percent in the third quarter of 2026, while MedTech operational sales grew 2.5 percent, according to Johnson & Johnson. The contrast places more weight on pharmaceutical launches and less on the device business for the near-term growth profile.

Dividend dates set for November

Johnson & Johnson declared a fourth-quarter 2026 cash dividend of USD 1.34 per share on October 13, 2026. The ex-dividend date is November 24, 2026, and the payment date is December 8, 2026.

The company has also scheduled its Enterprise Business Review for December 8, 2026, when management plans to discuss the 2027 outlook, according to Johnson & Johnson. That date gives investors a further point for assessing whether the current guidance is supported by the pipeline and MedTech recovery plan.

Stock holds above the Xetra close

Johnson & Johnson stock was trading at EUR 223.58 at Lang & Schwarz on October 14, 2026, at 12:13 p.m. CEST. That was 0.64 percent above the Xetra close of October 13, 2026 at EUR 222.15, calculated from the two euro values. The primary listing is on the NYSE in USD, while the reference quote here is the German euro quotation.

The further course of trading is shown by the continuously updated real-time quote of Johnson & Johnson stock.